Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4LEUT)

• Drug Name: PMID24210504C1o Drug Info
• Synonyms: GTPL8143; BDBM50444090

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 44256277
  TTD Drug ID: DM4LEUT

Molecule-Related Drug Atlas

Drug(s) Targeting Proto-oncogene c-Met (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[2]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[3]
Amivantamab	DMZ7AMY	Non-small-cell lung cancer	2C25	Approved	[4]
Capmatinib	DMYCXKL	Non-small-cell lung cancer	2C25.Y	Approved	[5]
Tepotinib	DMUQ0E8	Non-small-cell lung cancer	2C25	Approved	[6]
RG3638	DMTQJE0	Gastric adenocarcinoma	2B72	Phase 3	[7]
Savolitinib	DMALFKX	Renal cell carcinoma	2C90	Phase 3	[8]
Beperminogene perplasmid	DM6RWBN	Critical limb ischemia	BD4Y	Phase 3	[9]
Tivantinib	DMNVP8Q	Hepatocellular carcinoma	2C12.02	Phase 3	[10]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[7]

Drug(s) Targeting Beta-adrenergic receptor kinase 1 (ADRBK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9493490, E	DMFCIGE	N. A.	N. A.	Patented	[11]
US9493490, D	DMUVC25	N. A.	N. A.	Patented	[11]
US9493490, C	DMC1YR5	N. A.	N. A.	Patented	[11]
BDBM50173306	DMSTD28	N. A.	N. A.	Patented	[12]
US9493490, L	DMJDTSN	N. A.	N. A.	Patented	[11]
PMID21596927C101	DM7JRHB	Discovery agent	N.A.	Investigative	[13]
BetaARKct	DMN7DJ5	Discovery agent	N.A.	Investigative	[14]

Drug(s) Targeting G protein-coupled receptor kinase 5 (GRK5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BDBM50173323	DM7RTQP	N. A.	N. A.	Patented	[12]
BDBM50173330	DM1PU37	N. A.	N. A.	Patented	[12]
BDBM50173327	DMKEVDL	N. A.	N. A.	Patented	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Beta-adrenergic receptor kinase 1 (ADRBK1)	TTAZ3MN	ARBK1_HUMAN	Inhibitor	[1]
G protein-coupled receptor kinase 5 (GRK5)	TTTCXO0	GRK5_HUMAN	Inhibitor	[1]
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Inhibitor	[1]

References

• [1] Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6711-6.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Clinical pipeline report, company report or official report of Exelixis (2011).
• [4] Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
• [11] Boron-containing small molecules. US9493490.
• [12] G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564.
• [13] Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. Mol Pharmacol. 2011 Aug;80(2):294-303.
• [14] Gene-mediated inhibition of the b-adrenergic receptor kinase: a new therapeutic strategy for heart failure. Minerva Cardioangiol. 2001 Dec;49(6):389-94.